CO2020010269A2 - Variantes fc con unión mejorada a fcrn y semivida prolongada - Google Patents
Variantes fc con unión mejorada a fcrn y semivida prolongadaInfo
- Publication number
- CO2020010269A2 CO2020010269A2 CONC2020/0010269A CO2020010269A CO2020010269A2 CO 2020010269 A2 CO2020010269 A2 CO 2020010269A2 CO 2020010269 A CO2020010269 A CO 2020010269A CO 2020010269 A2 CO2020010269 A2 CO 2020010269A2
- Authority
- CO
- Colombia
- Prior art keywords
- variants
- life
- binding polypeptides
- fcrn binding
- long half
- Prior art date
Links
- 101150050927 Fcgrt gene Proteins 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 abstract 4
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 4
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 4
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000013604 expression vector Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 238000003259 recombinant expression Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
- C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862622468P | 2018-01-26 | 2018-01-26 | |
| PCT/US2019/015204 WO2019147973A1 (en) | 2018-01-26 | 2019-01-25 | Fc variants with enhanced binding to fcrn and prolonged half-life |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2020010269A2 true CO2020010269A2 (es) | 2020-12-10 |
Family
ID=65520379
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2020/0010269A CO2020010269A2 (es) | 2018-01-26 | 2020-08-20 | Variantes fc con unión mejorada a fcrn y semivida prolongada |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20190263934A1 (enExample) |
| EP (1) | EP3743441A1 (enExample) |
| JP (2) | JP7399880B2 (enExample) |
| KR (2) | KR20250008975A (enExample) |
| CN (2) | CN111788221A (enExample) |
| AU (2) | AU2019212638B2 (enExample) |
| BR (1) | BR112020015006A2 (enExample) |
| CA (1) | CA3089602A1 (enExample) |
| CO (1) | CO2020010269A2 (enExample) |
| IL (2) | IL318916A (enExample) |
| MX (2) | MX2020007882A (enExample) |
| MY (1) | MY203898A (enExample) |
| PH (1) | PH12020551134A1 (enExample) |
| SG (1) | SG11202006905YA (enExample) |
| TW (1) | TW201940512A (enExample) |
| WO (1) | WO2019147973A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL318916A (en) * | 2018-01-26 | 2025-04-01 | Genzyme Corp | FC variants with improved binding to FCRN and extended half-life |
| TW202120539A (zh) * | 2019-07-25 | 2021-06-01 | 美商健臻公司 | 以FcRn拮抗劑治療抗體媒介之病症的方法 |
| EP4037711A4 (en) | 2019-10-03 | 2024-02-14 | Atyr Pharma, Inc. | COMPOSITIONS AND METHODS USING ANTI-NRP2 ANTIBODIES |
| MX2022014150A (es) * | 2020-05-11 | 2023-02-27 | Invetx Inc | Composiciones para aumentar la semivida de un agente terapeutico en caninos y metodos de uso. |
| AU2021367988A1 (en) * | 2020-10-29 | 2023-05-11 | Formycon Ag | Ace2 fusion proteins and uses thereof |
| US12297273B2 (en) | 2021-05-27 | 2025-05-13 | Sanofi | Fc variant with enhanced affinity to Fc receptors and improved thermal stability |
| EP4388004A1 (en) | 2021-08-20 | 2024-06-26 | Intervet International B.V. | Antibodies and igg fusion proteins with an extended half-life |
| WO2023064841A1 (en) * | 2021-10-13 | 2023-04-20 | The Wistar Institute Of Anatomy And Biology | Antibodies for use against sars-cov-2 |
| AU2023274452A1 (en) | 2022-05-27 | 2025-01-16 | Innate Pharma | Natural killer (nk) cell engagers binding to nkp46 and bcma variants with fc-engineering |
| CN116162171B (zh) * | 2022-10-13 | 2025-06-03 | 深圳市百士通科技开发有限公司 | 抗体突变方法在治疗性抗体药物中的应用 |
| AR130869A1 (es) | 2022-10-25 | 2025-01-29 | Ablynx Nv | Polipéptidos de variantes de fc diseñados por glicoingeniería con función efectora aumentada |
| EP4630455A1 (en) | 2022-12-05 | 2025-10-15 | Sanofi | Transferrin receptor binding proteins |
| TW202535925A (zh) | 2023-10-25 | 2025-09-16 | 比利時商艾伯霖克斯公司 | 具有增強的Ｆｃ受體結合之Ｆｃ結構域變體 |
| WO2025101094A1 (en) * | 2023-11-08 | 2025-05-15 | Ооо «Geropharm» | Fc fragment polypeptide for producing therapeutically active fusion polypeptides and conjugates |
| WO2025149633A1 (en) | 2024-01-12 | 2025-07-17 | Laigo Bio B.V. | Bispecific antigen binding proteins |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5837821A (en) | 1992-11-04 | 1998-11-17 | City Of Hope | Antibody construct |
| WO1997014719A1 (en) | 1995-10-16 | 1997-04-24 | Unilever N.V. | A bifunctional or bivalent antibody fragment analogue |
| GB9524973D0 (en) | 1995-12-06 | 1996-02-07 | Lynxvale Ltd | Viral vectors |
| ES2694002T3 (es) * | 1999-01-15 | 2018-12-17 | Genentech, Inc. | Polipéptido que comprende una región Fc de IgG1 humana variante |
| CA2410551A1 (en) | 2000-06-30 | 2002-01-10 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw (Vib) | Heterodimeric fusion proteins |
| EP2502935B1 (en) | 2003-08-22 | 2017-03-29 | Biogen MA Inc. | Improved antibodies having altered effector function and methods for making the same |
| KR20070057839A (ko) * | 2004-08-19 | 2007-06-07 | 제넨테크, 인크. | 변경된 이펙터 기능을 갖는 폴리펩티드 변이체 |
| US8802820B2 (en) | 2004-11-12 | 2014-08-12 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| CN102746404B (zh) | 2004-11-12 | 2016-01-20 | 赞科股份有限公司 | 对FcRn的结合被改变的Fc变体 |
| ES2523666T3 (es) | 2005-05-31 | 2014-11-28 | Board Of Regents, The University Of Texas System | Anticuerpos IgG1 con la parte Fc mutada para el aumento de unión al receptor FcRn y usos de los mismos |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| EP2050764A1 (en) | 2007-10-15 | 2009-04-22 | sanofi-aventis | Novel polyvalent bispecific antibody format and uses thereof |
| US8775090B2 (en) * | 2008-12-12 | 2014-07-08 | Medimmune, Llc | Crystals and structure of a human IgG Fc variant with enhanced FcRn binding |
| BR112012015740B1 (pt) * | 2009-12-23 | 2020-09-29 | Synimmune Gmbh | Anticorpo anti-flt3, seu uso,bem como composição compreendendo o referido anticorpo e molécula de ácido nucleico |
| WO2011089211A1 (en) * | 2010-01-22 | 2011-07-28 | Synimmune Gmbh | Anti-cd133 antibodies and methods of using the same |
| TWI671315B (zh) | 2011-03-28 | 2019-09-11 | 法商賽諾菲公司 | 具有交叉結合區定向之雙重可變區類抗體結合蛋白 |
| GB201112429D0 (en) * | 2011-07-19 | 2011-08-31 | Glaxo Group Ltd | Antigen-binding proteins with increased FcRn binding |
| WO2013047748A1 (ja) | 2011-09-30 | 2013-04-04 | 中外製薬株式会社 | 複数の生理活性を有する抗原の消失を促進する抗原結合分子 |
| US20140294812A1 (en) * | 2013-03-15 | 2014-10-02 | Xencor, Inc. | Fc variants that improve fcrn binding and/or increase antibody half-life |
| CN105164157B (zh) * | 2013-04-29 | 2024-05-28 | 豪夫迈·罗氏有限公司 | Fc-受体结合的修饰的非对称抗体及使用方法 |
| HUE045466T2 (hu) * | 2014-11-06 | 2019-12-30 | Hoffmann La Roche | Fc-régió-variánsok módosított FcRn-kötéssel és alkalmazási eljárások |
| CN107074942A (zh) | 2014-11-10 | 2017-08-18 | 豪夫迈·罗氏有限公司 | 抗‑IL‑1β抗体和使用方法 |
| JP7464389B2 (ja) * | 2016-08-02 | 2024-04-09 | ビステラ， インコーポレイテッド | 操作されたポリペプチドおよびその使用 |
| IL318916A (en) * | 2018-01-26 | 2025-04-01 | Genzyme Corp | FC variants with improved binding to FCRN and extended half-life |
-
2019
- 2019-01-25 IL IL318916A patent/IL318916A/en unknown
- 2019-01-25 KR KR1020247043107A patent/KR20250008975A/ko active Pending
- 2019-01-25 US US16/258,080 patent/US20190263934A1/en active Pending
- 2019-01-25 SG SG11202006905YA patent/SG11202006905YA/en unknown
- 2019-01-25 MX MX2020007882A patent/MX2020007882A/es unknown
- 2019-01-25 AU AU2019212638A patent/AU2019212638B2/en active Active
- 2019-01-25 CN CN201980015900.4A patent/CN111788221A/zh active Pending
- 2019-01-25 CA CA3089602A patent/CA3089602A1/en active Pending
- 2019-01-25 WO PCT/US2019/015204 patent/WO2019147973A1/en not_active Ceased
- 2019-01-25 JP JP2020561607A patent/JP7399880B2/ja active Active
- 2019-01-25 EP EP19707152.5A patent/EP3743441A1/en active Pending
- 2019-01-25 BR BR112020015006-1A patent/BR112020015006A2/pt unknown
- 2019-01-25 TW TW108102958A patent/TW201940512A/zh unknown
- 2019-01-25 KR KR1020207024432A patent/KR102748986B1/ko active Active
- 2019-01-25 CN CN202411307275.XA patent/CN119350481A/zh active Pending
- 2019-01-25 IL IL276286A patent/IL276286B2/en unknown
- 2019-01-25 MY MYPI2020003848A patent/MY203898A/en unknown
-
2020
- 2020-07-24 MX MX2025009543A patent/MX2025009543A/es unknown
- 2020-07-24 PH PH12020551134A patent/PH12020551134A1/en unknown
- 2020-08-20 CO CONC2020/0010269A patent/CO2020010269A2/es unknown
-
2023
- 2023-12-04 JP JP2023204313A patent/JP2024026255A/ja active Pending
-
2025
- 2025-06-26 AU AU2025204826A patent/AU2025204826A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN119350481A (zh) | 2025-01-24 |
| JP2024026255A (ja) | 2024-02-28 |
| KR20200115568A (ko) | 2020-10-07 |
| MY203898A (en) | 2024-07-23 |
| PH12020551134A1 (en) | 2021-05-31 |
| MX2025009543A (es) | 2025-09-02 |
| IL276286B1 (en) | 2025-03-01 |
| EP3743441A1 (en) | 2020-12-02 |
| IL276286B2 (en) | 2025-07-01 |
| WO2019147973A1 (en) | 2019-08-01 |
| BR112020015006A2 (pt) | 2020-12-29 |
| SG11202006905YA (en) | 2020-08-28 |
| AU2019212638A1 (en) | 2020-09-17 |
| CN111788221A (zh) | 2020-10-16 |
| KR20250008975A (ko) | 2025-01-16 |
| CA3089602A1 (en) | 2019-08-01 |
| AU2019212638B2 (en) | 2025-04-03 |
| IL276286A (en) | 2020-09-30 |
| US20190263934A1 (en) | 2019-08-29 |
| JP2021511830A (ja) | 2021-05-13 |
| TW201940512A (zh) | 2019-10-16 |
| IL318916A (en) | 2025-04-01 |
| MX2020007882A (es) | 2020-12-03 |
| AU2025204826A1 (en) | 2025-07-17 |
| JP7399880B2 (ja) | 2023-12-18 |
| RU2020128177A (ru) | 2022-02-28 |
| NZ767453A (en) | 2025-03-28 |
| KR102748986B1 (ko) | 2025-01-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2020010269A2 (es) | Variantes fc con unión mejorada a fcrn y semivida prolongada | |
| CO2021002907A2 (es) | Constructos de anticuerpos para cldn18.2 y cd3 | |
| DOP2019000011A (es) | Proteínas de unión de tipo anticuerpo biespecíficas que se unen específicamente a cd3 y cd123 | |
| MX2020010235A (es) | Vectores de expresion para receptores de engullimiento quimerico, celulas hospederas geneticamente modificadas y usos de los mismos. | |
| PE20220231A1 (es) | Proteinas de fusion flt3l-fc y metodos de uso | |
| CL2021001835A1 (es) | Neoantígenos prostáticos y sus usos. | |
| MX2023007211A (es) | Anticuerpos antimiostatina y metodos de uso. | |
| CO2019003809A2 (es) | Anticuerpos contra proteína alfa reguladora de señal y métodos de uso | |
| MX2017004664A (es) | Conjugados de farmacos de anticuerpos modificados mediante glicoingenieria. | |
| MX2021013161A (es) | Polipeptidos que contienen dominios de union de novo y usos de los mismos. | |
| BR112019004711A2 (pt) | receptores de antígeno quiméricos compreendendo domínios de fibronectina tipo iii específicos para bcma e usos dos mesmos | |
| MX2022000367A (es) | Heterodimeros, metodos y uso de los mismos. | |
| MX2015000397A (es) | Complejo del factor viii con xten y proteina del factor von willebrand, y sus usos. | |
| EA202091198A1 (ru) | Полипептиды, содержащие домен d, и их применение | |
| ECSP15014133A (es) | Polipéptidos que contienen fc con glicosilación alterada y función efectora reducida | |
| PE20181275A1 (es) | Ensamble de polipeptido quimerico y metodos para hacer y usar el mismo | |
| MX2017010721A (es) | Interruptores transcripcionales activados mediante unión y métodos para su uso. | |
| MX2018007485A (es) | Variantes de enzimas y polinucleotidos que las codifican. | |
| EA202092093A1 (ru) | Композиции и способы перепрограммирования tcr с применением слитых белков | |
| CL2017000200A1 (es) | Célula huésped mejorada para producir proteinas | |
| EA202190267A1 (ru) | Способы и композиции с использованием рекомбинантных дендритных клеток для терапии рака | |
| BR112018005464A2 (pt) | expressão de proteínas contendo fc | |
| MX2021005308A (es) | Receptores de celulas t especificos para mesotelina y su uso en inmunoterapia. | |
| MX2023012707A (es) | Anticuerpos de la proteina inmunorreceptora de celulas t con dominios ig e itim (anti-tigit) y metodos de uso de estos. | |
| BR112019004017A2 (pt) | proteínas quiméricas para direcionar dsrna |